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ORIGINAL ARTICLE 
Metastatic melanoma mortality in Malta 
Liam Mercieca, Kristie Tonna, Alexandra Betts, Susan Aquilina
BACKGROUND 
There are currently no studies looking specifically at the 
characteristics of the primary melanoma in patients who died of 
metastatic melanoma in Malta. This retrospective study looks at the 
demographics of these patients and the characteristics of their 
primary melanoma.  
METHOD 
Mortality data secondary to metastatic melanoma between 2007 and 
2016 was gathered from the Malta National Mortality Registry. All 
patients whose death certificates had metastatic melanoma as the 
cause of death were included. Further data on histology and imaging 
was gathered from the Malta National Cancer Registry and the 
hospital electronic database. 
RESULTS 
There were 87 recorded deaths (45 male; 42 female) in Malta 
secondary to metastatic melanoma between 2007 and 2016, with an 
average age at diagnosis of the primary melanoma of 64.3 years 
(range 23-92 years), average age at death of 67.9 years (range 28-96 
years) and an average duration of survival after diagnosis of primary 
melanoma of 34.7 months (range 1-180 months). The commonest 
histological subtype of the primary cutaneous melanoma was 
nodular. The commonest site for the primary cutaneous melanoma 
was the back. The mean Breslow thickness was 4.23mm (range 0.3-
13mm). The commonest site of metastasis was to distant lymph 
nodes, followed by the skin, liver and lung.  
CONCLUSION 
Mortality secondary to metastatic melanoma is prevalent in the over 
60 age group, with the back being the commonest site of the primary 
melanoma. Identification of patients who are at higher risk of death 
from melanoma in Malta allows for their more effective targeting in 
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INTRODUCTION 
Melanoma is the most serious form of skin 
cancer, due to the significant risk of metastasis 
and death. Risk factors for cutaneous 
melanoma include sun exposure, increasing 
number of moles on the skin, the presence of 
atypical moles, fair skin, family or personal 
history of melanoma, immunosuppression and 
increasing age.1 The ABCDE (asymmetry, 
border, colour change, diameter, evolution) 
pattern and the ugly duckling sign are useful 
educational tools to help the general public 
pick up any warning signs for melanoma.2 
The Maltese islands have a high UV index for 
several months of the year with the population 
being exposed to intense sunlight particularly 
in the spring and summer months. The majority 
of the population is of skin phototype II to IV.3 
This means that a significant percentage of the 
population is susceptible to skin burning when 
exposed to the sun, which is a risk factor for 
the development of melanoma. In Malta, 
melanoma incidence has been on the increase 
over the past twenty years,4 a trend which has 
been observed in white populations 
worldwide.5-8 The standardised incidence for 
primary invasive cutaneous malignant 
melanoma in Malta increased from 3.7 per 
100,000 population per year for males and 5.1 
for females between 1993-1997, to 10.1 per 
100,000 population per year for males and 12.1 
for females in 2017.4 Despite this, mortality 
from melanoma has remained stable between 
2007 and 2017,4 presumably because the 
increased incidence is mainly for thin 
melanomas of low metastasizing potential.6 
Established bad prognostic factors indicating a 
higher risk of death in patients with cutaneous 
melanoma include increasing tumour 
thickness (Breslow thickness), ulceration, 
mitotic rate, number of metastatic nodes, 
clinically apparent nodal metastasis and 
visceral metastasis.9 
Traditionally, the treatment of cutaneous 
melanoma has involved surgical excision with 
narrow margins, followed by wider surgical 
excision with margins guided by the Breslow 
thickness (Table 1).10 Sentinel lymph node 
biopsy (SLNB), performed at the time of the 
wider excision,10 is offered to patients 
depending on the Breslow thickness (>1mm) 
and other high risk factors. SLNB for 
melanoma has been offered in Malta since May 
2010.  Further investigation (blood tests, 
ultrasound, CT, PET scans etc) would be 
indicated according to the prognosis of the 
patient; most patients with thin melanomas 
(Breslow thickness <1 mm) would be treated 
only with surgery and close clinical follow up.  
Table 1 Recommended excision margins 
 of a primary melanoma depending 




excision margin, cm 
In situ 0.5 
≤ 1.0  1  
1.01-2.00 1-2  
2.01-4.00 1-2  
> 4.0  2 
 
There are no studies looking specifically at the 
demographics of patients dying of metastatic 
melanoma in Malta, or the characteristics of 
their primary melanoma. This retrospective 
study aims to look at these factors, to help 
identify the patients who are at a higher risk of 
death from melanoma in Malta, so they may be 
targeted more effectively in local melanoma 
screening and education campaigns.   
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METHODS 
Data for this study was collected 
retrospectively from the Malta National 
Mortality Registry. All patients whose death 
certificates listed metastatic melanoma as the 
cause of death between 2007 and 2016 were 
included in the study. Further data on 
histology and imaging was gathered from the 
Malta National Cancer Registry and the 
hospital electronic database when available. 
Data collected included demographic details, 
date of diagnosis of the primary melanoma, 
date of death, melanoma histological subtype, 
site of primary melanoma, Breslow thickness, 
Clark’s level, presence of ulceration, lymph 
node involvement including sentinel lymph 
node biopsy result and site of distant 
metastasis when imaging was available.  
RESULTS 
There were 87 recorded deaths (45 were male 
and 42 were female) secondary to metastatic 
melanoma in the ten-year period between 
2007 and 2016. The primary melanoma was 
identified histologically in 57 cases (66%), 
whilst 24 cases (27%) had confirmed 
metastatic melanoma on histology and 
imaging, but the primary melanoma was not 
identified. The remaining 6 cases (7%) 
originated from an extra-cutaneous primary 
site. The commonest histological subtype of 
the primary cutaneous melanoma was nodular 
followed by superficial spreading and acral 
melanoma (Table 2a). The commonest site for 
the primary melanoma was the back, followed 
by the hands and feet (acral), followed by the 
legs (Table 2b). 
 
Table 2a Histological subtype of the primary melanoma 
Melanoma histological subtype Percentage (number of cases,n=87) 
Male(M), Female (F) 
Nodular 25% (n=22; M16:F6) 
Superficial spreading 17% (n=15; M8: F7) 
Acral lentiginous 15% (n=13; M3:F10) 
Other (balloon cell ,mucosal, desmoplastic, 
choroidal) 
7% (n=6; M2:F1) 
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Table 2b Site of the primary melanoma 
Site of primary Percentage (number of cases, n=87) 
Male(M), Female (F) 
Back 22% (n=19; M13:F6) 
Acral 15% (n=13; M10:F3) 
Legs 13% (n=11; M5:F6) 
Arms 9% (n=8; M4:F4) 
Head and neck 7% (n=6; M5:F1) 
Chest and abdomen 5% (n=4; M3:F1) 
Choroidal (eye) 2% (n=2; M0:F2) 
Genital 2% (n=2; M1:F1) 
Paranasal sinus 1% (n=1; M1:F0) 
Oral  1% (n=1; M1:F0) 
Lung pleura 1% (n=1) (M0:F1) 
Anal 1% (n=1) (M1:F0) 
Not available/Primary not identified 21% (n=18) 
 
The average age at diagnosis of the primary 
melanoma was 64.3 years (range 23-92 years, 
median 65 years), the average age at death 
was 67.9 years (range 28-96 years, median 69 
years) and the average duration of survival 
after diagnosis of the primary melanoma was 
34.7 months (range 1-180 months, median 19 
months). 
Table 3 shows the Breslow thickness and 
Clark’s level in the 57 cases (66%) where 
histology of the primary melanoma was 
identified. The mean Breslow thickness was 
4.35mm (range 0.3-13mm). Ulceration was 
present in 21 cases. Five patients who died of 
metastatic melanoma had a primary cutaneous 
melanoma with a Breslow thickness <1mm. 
Their characteristics are shown in Table 4. 
A sentinel lymph node biopsy result was 
available in a total of 30 cases; 28 of these 
were positive while 2 were negative. The 2 
cases that presented with a negative sentinel 
lymph node biopsy and eventual metastasis 
had their primary melanoma on the back and a 
Breslow thickness of 3.5 mm and 12 mm 
respectively. The commonest sites of distant 
metastasis were to distant lymph nodes, liver 
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Table 3 Breslow thickness and Clark’s level of the primary melanoma 
Breslow thickness Percentage (number of cases, n=57) 
In situ  0% (n=0) 
0.1 – 1.0mm 8% (n=5) 
1.01 – 2.0mm 18% (n=10) 
2.01 – 4.0mm 
32% (n=18) 
>4.0mm 42% (n=24) 
Clark level Percentage (number of cases, n=57) 
1 0% (n=0) 
2 4% (n=2) 
3 25% (n=14) 
4 56% (n=32) 
5 15% (n=9) 
 




























melanoma Left leg 0.7 3 N Brain 
















melanoma Left flank 0.93 3 N N/A 
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Table 5 Documented sites of metastasis (The same patient might have had two or more distant 
 metastasis sites. Data on the site of metastasis was not available in 39 cases) 
Site of metastasis Number (n=48) 









Our study shows that death from melanoma in 
Malta, as seen in other countries, is more 
common in the older age groups, with an 
average age at death of 67.9 years, occurring 
within an average of 34.7 months of diagnosis 
of the primary melanoma. Older people also 
show a higher incidence of melanoma, in Malta 
as well as worldwide, where melanoma 
incidence (age standardised) rates peak at the 
seventh and eighth decades of life.11 
The commonest histological type of melanoma 
causing metastasis and death in our cohort was 
nodular melanoma, followed by superficial 
spreading and acral melanoma. This does not 
come as a surprise as, although superficial 
spreading melanomas are the commonest 
form of melanoma, they tend to be diagnosed 
at less than 1 mm thickness, as opposed to 
nodular melanomas that tend to be thicker 
than 2 mm at the time of diagnosis and would 
therefore be associated with a worse 
prognosis.  
The back was the commonest skin site for the 
primary melanoma leading to death in our 
cohort. Among Caucasian populations, 
including the Maltese population, melanoma is 
more frequently reported on the backs and 
shoulders in men and on the lower limbs in 
women.5-6,11 The back should be emphasized in 
educational campaigns so that patients ensure 
that this part of their body is checked regularly 
by other family members, their doctor or 
friends, or else with the use of a mirror. Mole 
mapping in selected cases can be useful as a 
baseline photographic record for long-term 
screening in order to allow objective 
comparison and early detection of any changes 
in pigmented lesions, especially in areas that 
are difficult to monitor. The primary melanoma 
leading to metastasis was never identified in 
27%(n=24) of cases. This could be due to 
regression of the primary tumour or due to 
patients presenting at a terminal stage or the 
melanoma occurring in an inaccessible site. 
As expected, thick primary melanomas 
correlated with an increased risk of death. The 
mean Breslow thickness in our cohort was 
4.35mm and we had no patients dying of 
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metastatic melanoma who had presented with 
an in situ primary melanoma. However, 8% of 
the total deaths due to melanoma in our 
cohort had a primary melanoma with Breslow 
thickness of only 0.3 to 1 mm and showed no 
ulceration. Internationally, patients with a 
primary melanoma with Breslow thickness <1 
mm have a 95% 5-year survival rate.12 Our 
results do remind us that patients in the thin 
melanoma category may – rarely – still develop 
metastases and die from them. 
Sentinel lymph node biopsy carried out in our 
cohort was positive in 38 cases and negative in 
only 2. Several international large-scale 
studies have reported a relatively high false-
negative rate for SLNB (5.6-21%).13 The false 
negative rate of SLNB biopsy in Malta cannot 
be determined from this study as we only 
studied patients who died of melanoma. 
However, our results do highlight the small 
possibility of a false negative result with a 
SLNB biopsy, which should be communicated 
to the patient. 
A limitation of the study is the small number of 
patients, despite including the whole 
population on the islands over a 10-year 
period. Data on the primary melanoma was 
unavailable in about one fourth of cases since 
these patients were diagnosed at the 
metastatic stage. Patients included in the 
study had metastatic melanoma as the primary 
cause of death on their death certificate. 
However, co-morbidities which may have 
contributed to death were not taken into 
account in this study. The site of metastasis 
was unavailable or undocumented in a number 
of cases and patients may have had 
undocumented metastases elsewhere.  
In recent years, the management of melanoma 
has undergone some very important changes. 
Up to a few years ago, due to the absence of 
effective systemic therapy options, surgery 
was viewed as the only potential curative 
treatment. A big leap in the treatment of 
metastatic melanoma occurred with the 
advancement of new systemic therapies, 
including immunotherapy with cell cycle 
checkpoint inhibitors (e.g. nivolumab and 
pembrolizumab) and targeted therapies aimed 
at BRAF and MEK mutations (including 
dabrafenib and trametinib), which may also be 
used in the adjuvant setting. These treatments 
became available in Malta in recent years. 
There has also been a move away from 
performing complete lymph node dissection in 
patients with a positive sentinel lymph node 
(clinically occult disease), as no overall survival 
benefit was shown over observation with 
nodal basin ultrasound surveillance in two 
large prospective randomized phase III studies 
(MSLT-II and DeCOG).14  These patients would 
now be offered adjuvant therapy, so the role 
of SLNB is changing from that of a prognostic 
indicator to one that influences access to 
adjuvant treatment.15 The American Joint 
Committee on Cancer (AJCC) published the 
eighth edition of its staging system for 
melanoma in 2017,12 to move towards a ‘more 
personalized’ approach to the treatment of 
melanoma. It is hoped that future studies on 
melanoma mortality in Malta will reflect the 
positive influence of these new management 
strategies.  
Finally, local campaigns to advise the public 
not to overexpose their skin to the sun should 
also be continued and promoted, together 
with campaigns to encourage earlier detection 
and treatment of melanomas when they 
present on the skin or accessible parts of the 
body. With this three-pronged approach of 
primary prevention of melanoma, early 
detection and treatment, and improved 
management of patients with metastatic 
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melanoma, we hope that as few patients as 
possible will succumb to this cancer.   
CONCLUSION 
This study has provided more local data on 
melanoma to help in the fight against this 
cancer. It confirms that death from melanoma 
is highest in patients over 60 years of age. It 
also highlights the importance for individuals 
to have their backs checked since this is the 
commonest primary melanoma site leading to 
mortality. 
SUMMARY BOX 
What is known: 
 Melanoma causes significant mortality 
 Early diagnosis is key 
 Latest guidelines on staging updated 
 New treatments available 
New findings: 
 There has been a rise in melanoma 
incidence but not mortality in Malta over 
the past 10 years 
 Death from melanoma in Malta is 
commonest in the over 60 age group. 
 The characteristics of the primary 
melanoma leading to metastatic 
melanoma in Malta have been identified. 
The commonest site for the primary was 
the back, with nodular melanoma being 
the commonest histological type.  
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